Pramlintide vs Retatrutide
Overview
Pramlintide and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Pramlintide and Retatrutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pramlintide | Retatrutide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | Research use only | Research use only |
| Typical dosage | 60-120 mcg | Clinical trials |
| Frequency | with meals | weekly |
| Reported benefits | Reduced post-meal glucose, weight loss, appetite control | Enhanced weight loss beyond dual agonists, metabolic improvement |
| Reported side effects | Nausea, hypoglycemia risk with insulin | Clinical trial phase |
Key differences
Primary use. Pramlintide is categorised under Weight Management & Metabolic, while Retatrutide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Pramlintide: not FDA-approved; treated as a research compound. Retatrutide: not FDA-approved; treated as a research compound.
Dosing. Pramlintide is typically dosed at 60-120 mcg (with meals). Retatrutide is typically dosed at Clinical trials (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Pramlintide and Retatrutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pramlintide and Retatrutide?
- Pramlintide and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Pramlintide is not FDA-approved; generally classified as a research compound, whereas Retatrutide is not FDA-approved; generally classified as a research compound.
- What is Pramlintide used for?
- Amylin analog for diabetes.
- What is Retatrutide used for?
- Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026.
- Can you take Pramlintide and Retatrutide together?
- Some users combine peptides within a single protocol, but stacking Pramlintide and Retatrutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pramlintide or Retatrutide FDA-approved?
- Pramlintide is not FDA-approved; generally classified as a research compound. Retatrutide is not FDA-approved; generally classified as a research compound.
Read the full articles
- Pramlintide — full monograph: mechanism, research, dosing & references
- Retatrutide — full monograph: mechanism, research, dosing & references